Does this suggest little has been achieved / improved over the...

First 232 Last

Share
Profile

Follow
caj1smithy

93 Posts.

89

04/04/20

13:00

Post #: 43877120
Share

Originally posted by exchanger: ↑

Level 8, 261 George Street Sydney NSW 2000 Tel: (61-2) 9247 8212 Fax: (61-2) 9247 3932 E-mail: [email protected] Website: www.biotron.com.au 10 November 2004 The Manager - Companies Australian Stock Exchange Limited 20 Bridge Street SYDNEY NSW 2000 (1 page by email) Dear Madam, SARS VIRUS TREATMENT TARGET IDENTIFIED The Directors are pleased to advise that a Biotron Limited ('Biotron') manuscript describing that the E protein of SARS coronavirus forms ion channels has been subjected to vigorous peer-review and published in the prestigious international scientific journal, Virology. Based on the initial work described in the manuscript, Biotron has: o developed a rapid screening assay for the E protein target; o screened Biotron’s library of rationally-designed small-molecule compounds for activity against the target; o identified compounds with good activity against SARS and other viruses within the coronavirus family including viruses that cause an estimated 25% of cases of the common cold as well as significant veterinary viral diseases; and o shown these compounds to inhibit replication of the virus by having the compounds independently tested for antiviral activity against the SARS coronavirus. The results of these studies demonstrate the potential of the SARS E protein as a target for therapeutic intervention to treat this disease. More significantly, the results of this work further validate the Company's anti-viral platform technology which has been shown to be effective against a number of families of viruses including coronaviruses (SARS), flaviviruses (Dengue), HIV and Hepatitis C. Biotron’s coronavirus studies have been supported in part by a Biotechnology Innovation Fund (BIF) grant from the Federal government. This work opens up a new way to treat these currently untreatable diseases. For further information, please contact Dr. Michelle Miller, CEO, on (61-2) 61258001. Yours sincerely Peter J. Nightingale Company Secretary pjn2791

https://www.biotron.com.au/wp-content/uploads/2013/04/Announcement10Nov04.pdf

Expand

Does this suggest little has been achieved / improved over the last 16 years research by BIT.?
How many pumps over the last few years? Looks like need care with this one
Upvote

Reply